Primary sclerosing cholangitis (PSC) is a rare and chronic liver disease for which there is no effective therapy. Interest has grown in developing treatments for this condition, with several agents proposed as potential therapies. However, there is a lack of clarity about how to measure clinical benefit in trials involving patients with this complex and rare disease. This article reviews regulatory information, the available literature on natural history, as well as potential candidate clinical and surrogate endpoints for PSC. (Hepatology 2018; 68:1174-1188).
P rimary sclerosing cholangitis (PSC) is a cholestatic liver disease characterized by inflammation and stricturing of the biliary tree. PSC is a rare disease with prevalence ranging from 0 to 16.2 per 100,000 inhabitants and qualifies for the status of an orphan disease in the United States* and EU.
(1) PSC has a high incidence of liver-related morbidity and mortality, cholangiocarcinoma (CCA), inflammatory bowel disease (IBD), and an increased risk for colorectal cancer (CRC). There is currently no approved therapy for PSC. Many immunomodulatory and antifibrotic agents have been studied in PSC, the majority of which did not progress beyond the early proof-of-concept phase. The only drug that may have a role in slowing disease progression is ursodeoxycholic acid (UDCA). However, despite two decades of clinical research, there is still no convincing evidence from randomized trials that UDCA is truly beneficial in improving transplant-free survival (TFS). Important factors complicating drug development for PSC include the complexity of the disease and the relatively long time for development of clear clinical outcomes, such as transplant or all-cause mortality or PSC-related mortality. There is lack of prospective natural history data from large, multicenter studies that could be useful in determining potential biomarkers that would be reasonably likely to predict clinical outcomes.
Designing clinical trials in PSC poses challenges, because of the heterogeneity of the disease, with varying rates of progression to cirrhosis and competing risk events, such as the occurrence and complications of CCA, dominant strictures, intercurrent bacterial cholangitis, IBD, and colon cancer. Therefore, any clinical trial with a therapy aimed at modifying the clinical course will need to include these events as primary, secondary, and safety endpoints.
A diagnosis of PSC is made according to the American Association for the Study of Liver Diseases (AASLD) or European Association for Study of the Liver guidelines. (2, 3) There is no firm criterion for diagnosis, and it may be that a cohort of patients with PSC may include a heterogeneous population with a variety of etiologies resulting in a common phenotype, but likely not all responding in the same way to the drug under study. As an example, a proportion of patients included in earlier trials may have been, in fact, patients with immunoglobulin (Ig)G4-associated cholangitis (IAC) given that IAC was only first described in 2007. (4) In March 2016, the United States Food and Drug Administration (FDA) and the AASLD organized a GREAT † workshop on trial design and endpoints for clinical trials in adults and children with PSC to promote drug development for this serious and life-threatening disease. During this conference, it became clear that many issues remain unresolved. This article reviews the available literature on natural history data and trial design in adult and pediatric PSC, and discusses regulatory information, as well as various potential clinical and surrogate endpoints.
Scope of the Problem

CliNiCal CoURse
PSC in adults is an idiopathic, inflammatory disease of the bile ducts, in which the majority of patients either have or will develop IBD. PSC patients frequently suffer from bacterial cholangitis and are at increased risk of developing hepatobiliary malignancies, most notably CCA. The cumulative risk of developing CCA has been estimated at 20% at 30 years after diagnosis of PSC. 5, 6 In patients who also suffer from IBD, the risk of developing CRC is up to 9-fold increased as compared to the background population. (5) Overall, median time to transplantation from the time of diagnosis depending on the population studied is 13-21 years. (5, 7) Common causes of death are liver failure and CCA. Indications for liver transplantation (LT) are end-stage liver disease (ESLD) and, occasionally, severe complaints such as intractable pruritus or recurrent bacterial cholangitis.
Cholestasis occurs relatively early in PSC compared to hepatocellular-based causes of cirrhosis, and portal hypertension tends to be presinusoidal with early development of varices without ascites; thus, commonly used models for cirrhosis development, such as the Child-Turcotte-Pugh classification and Model for End-Stage Liver Disease (MELD), may not always adequately predict outcomes. Moreover, the disease course can be highly variable, partly attributed to the unpredictable occurrence of malignancy and probably also because PSC is a heterogeneous disease, with some patients having an indolent course and others a more aggressive phenotype. Increasingly, subphenotypes have been described, which, in many cases, are associated with differences in clinical outcome (see Table 1 ). Patterns of alkaline phosphatase (ALP) elevations are different than observed in primary biliary cholangitis (PBC), in that they can fluctuate much more. ALP and other biomarkers are further discussed below.
CoNCURReNt iBD
Sixty percent to 80% of PSC patients either have or will develop IBD. The majority of patients with both PSC and IBD have ulcerative colitis (UC); approximately 10% have Crohn's disease and 10% indeterminate colitis. In cases of Crohn's disease, there is almost always involvement of the colon. (20) Concurrent IBD either can be used for stratified randomization at enrollment (as yes or no) or may be considered as an eligibility factor for recruitment in trials. Concurrent aRtiCle iNFoRMatioN: IBD treatment(s) may have a confounding effect on the efficacy of the investigational agent and should be controlled during the clinical trial. PSC progression has traditionally been thought to run an independent course from bowel disease activity. However, a recent article reported that clinically progressive PSC requiring LT is associated with milder UC disease activity, including less use of steroids, azathioprine, and need for surgery. (21) Moreover, in a recent cohort of >7,000 PSC patients, concurrent Crohn's disease or no IBD were associated with a lower risk of LT or death compared to UC. (9) A combination of patient-reported outcomes and endoscopic assessment are now considered the standard outcome measures for clinical trials in IBD and should be included in clinical trials for populations with PSC and IBD. Given the phenotypic difference in IBD in PSC patients, there are no instruments specifically developed that assess the symptoms of IBD in PSC patients. The higher incidence of CRC in PSC patients requires surveillance and should be a safety endpoint for the drug studied in clinical trials. Current practice guidelines require annual surveillance colonoscopies in PSC/IBD patients. (22) 
DoMiNaNt stRiCtURes
Dominant strictures (DSs) are arbitrarily defined as having a diameter of less than 1.5 mm in common bile duct/common hepatic duct or <1.0 mm in the left/ right main duct. (23) In fact, any stricture arising in these ducts that leads to increase in cholestatic biochemical parameters and/or symptoms is clinically considered DS. The terminology needs to be standardized to allow comparison of data across different clinical trials. During the natural course of large-duct PSC, the incidence of DS is estimated at 5%-10% annually. In two long-term longitudinal cohorts of PSC patients in whom repeat endoscopic retrograde cholangiographies (ERCs) were performed, 57%-62.5% of patients had or developed at least one DS within a median follow-up of 5-9 years respectively. (24, 25) DSs were found to be associated with poorer TFS, which was partly attributable to CCA, which also manifests itself as DS in many cases. (25, 26) Whether DSs impact disease course by increasing biliary pressure or are merely a hallmark of advanced disease remains elusive. Of note, a definition of DS on magnetic resonance imaging (MRI) islacking and was identified as one the research priorities in the recent International PSC Study Group (IPSCSG) position statement paper on the use of MRI. (27) CCa PSC may be considered a premalignant disease, given that the risk of developing CCA is increased 400-fold over the general population. (5, 6) Three concerns related to the issue of CCA with regard to clinical trials are noteworthy: (1) how to screen for the presence of unrecognized CCA at trial entry; (2) how Crohn's colitis Higher TFS attributed to more small-duct disease (10) (11) (12) No IBD Older age of diagnosis, possibly higher TFS (9) Race White Black Younger age and higher MELD at LT listing compared to whites (13) Serum ALP Normal Higher TFS (14) (15) (16) Elevated Lower TFS (17, 18) IgG4 Normal IgG4 Possibly higher TFS?
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to monitor for CCA development during a clinical trial; and (3) how to structure chemoprevention trials for CCA in PSC.
There are no evidence-based guidelines on the best surveillance strategies for CCA in PSC. Nonetheless, most specialists in the PSC field would agree that anMRI and magnetic resonance cholangiography (MRC) displaying no mass lesions, nor vascular encasement, nor a dominant stricture; as well as a cancer antigen 19.9 (CA 19.9) <130 U/mL would make the presence of CCA unlikely. (28) Accounting for CCA development during the course of a clinical trial is complex, given that this could be regarded either as a competing risk or as a clinical outcome and, depending on the mechanism of the drug, could be a primary, secondary, or safety endpoint. An immunomodulatory investigational drug may have a bimodal effect on CCA risk, because resolution of inflammation may decrease the risk of CCA, whereas decreased tumor surveillance may promote the opposite. Surveillance during clinical trials could include serum CA 19.9 and annual MRI/ MRC. (6, 27, 28) In experienced hands, ultrasound may be an alternative, given that in a retrospective study from a tertiary referral center it was shown to have equal diagnostic performance with higher accuracy. (29) Chemoprevention trials could potentially be enriched to target patients that have no mass lesion on MRI/MRC and a serum level of CA 19.9 <130 U/ mL, but suspicious cytology and/or polysomy on fluorescent in situ hybridization. Intensive follow-up with ERC and sampling would be mandatory in such trials.
peDiatRiC psC
Childhood PSC is quite rare, with approximately 150 new cases diagnosed annually in the United States. Overlap with autoimmune hepatitis (AIH) occurs in approximately 1 in 3 of cases. PSC is more than twice as common in pediatric IBD as compared to adults, with up to 10% of pediatric IBD patients diagnosed with PSC. Of note, concurrent PSC is the most significant source of major morbidity in pediatric IBD patients. Because of the rarity of the disease, observational data on clinical outcomes are limited. In a series of 192 PSC children from five centers, transplant rates ranged from 19% to 45% after a median disease duration of 5.0-12.7 years. To meet the knowledge gap in pediatric PSC, a multicenter data collection on PSC patients from over 36 pediatric centers worldwide was initiated. Results show that elevations in bilirubin, gamma-glutamyltransferase (gGT), and aspartate aminotransferase-to-platelet ratio index at diagnosis can identify patients at highest risk; small-duct PSC and concurrent IBD are more favorable disease phenotypes. (30) Clinical trials in pediatric patients with PSC may need innovative trial designs. Investigators are encouraged to interact with regulatory agencies early in drug development.
patieNt eXpeRieNCe
An important issue raised by patient advocacy groups, such as PSC Partners for Cure and PSC Support UK, is the frequent discrepancy between the physician's assessment of the patient's clinical status and the patient's own assessment of their well-being. Current biochemical measurements and imaging techniques fail to capture debilitating symptoms, such as chronic fatigue and pruritus. Main concerns for PSC patients are uncertainty about the future, including fear of dying, as well as becoming a burden to others. Patients have expressed their desire to have treatments directed at the underlying disease, reduction in the risk of cancer, as well as treatment the debilitating symptoms of fatigue and pruritus.
There is an urgent need to develop and validate tools for PSC for adequately measuring symptoms, such as fatigue and pruritus, and assess the health-related quality-of-life (QoL) scores that incorporate emotional domains. A survey among 546 UK patients showed that 85% scored fundamental research into finding a treatment and preventing CCA as the prime area of research to pursue (www.pscsupport.org.uk/fda). Willingness among PSC patients to participate in clinical trials is high, even if this requires burdensome invasive interventions such as liver biopsy, provided they get assurance that the intervention is critical to the study. In the United States, data from a recent patient focus group developed as part of a grant application to the Patient-Centered Outcomes Research Institute show similar areas of concern (www.pscpartnersregistry.org).
pReVioUs CliNiCal tRials iN psC
The past 20 years have seen 26 published, investigator-initiated clinical trials, and none of these publications were results from industry-sponsored trials. Recently, there is a resurgence of interest from the pharmaceutical industry for this orphan disease, and a handful of phase 2 trials are currently underway and two have presented results. Norursodeoxycholic acid, a side-chain-shortened C23 homologue of UDCA, showed a dose-dependent improvement of cholestasis in a 12-week, phase 2 multicenter study. (31) Simtuzumab, a humanized IgG4 monoclonal antibody against lysl oxidase like-2, failed to show a significant reduction compared to controls in mean hepatic collagen content in a 96-week phase 2b trial. (32) Endpoints that have been used in past clinical trials include serum biochemistries, primarily ALP and bilirubin, histopathology, and clinical outcomes, for example, the occurrence of events such as death, LT, complications of cirrhosis, and CCA. There have been four randomized controlled clinical trials in PSC that used clinical events as primary outcome parameters with a follow-up ranging from 2 to 5 years. (33) (34) (35) (36) One trial studied colchicine and the other three investigated UDCA. In three studies, no effect was observed on the occurrence of clinical outcomes such as TFS and cirrhosis-related symptoms. In one study of high-dose UDCA, an unexpected worsening in clinical outcome was observed in the study drug arm despite improvements in ALP. However, as discussed below, all four appear to be underpowered, which may, in part, be the reason why there is still ongoing debate about the efficacy of UDCA. The low event rate and limited duration in these four studies, which recorded clinical outcome in parallel with biochemical and/or histological measures, precludes assessment of the surrogate markers to predict clinical outcomes.
In the large Scandinavian trial with 5-year follow-up, the incidence of clinical events such as death and LT in the placebo groups was around 3% annually. This same figure has been observed in a large, population-based cohort of PSC patients. (5) This trial encompassed around 1,100 patient-years of follow-up, while they estimated to require 1,730 patient-years of follow-up to attain a power of 80%. The fact that no effect of UDCA could be detected on the composite primary endpoint of death or LT is likely attributed to the need for a larger power for this endpoint. The other UDCA study with 5-year follow-up used, in addition to death and LT, development of cirrhosis on repeat biopsy, varices, meeting minimal listing criteria for LT, or CCA as composite primary endpoint. (36) At the premature termination at 6 years, 26% of placebo-treated patients had reached the primary endpoint, which would translate to an average annual event rate of approximately 6%. As an example, assuming a constant annual event rate of 5% in the placebo group, one could estimate that a clinical trial with a 2:1 active drug versus placebo arm, an alpha = 0.05, an accrual time of 2 years, a follow-up time of 5 years, and a rather large effect size of 0.5 would need at least 400 patients to attain a power of 80%. This is hardly feasible in an orphan disease like PSC.
However, with different endpoints either using surrogates or a clinical benefit endpoint that included progression to cirrhosis and all decompensation events as well as death and LT would make a clinical trial feasible in this population. In addition, because PSC is a rare disease, both the FDA and the European Medicines Agency have been flexible in requirements for powering of these trials. (37) 
FDA Framework for Approval of Drugs
Federal regulations for approval of a drug require demonstration of substantial evidence of effectiveness. Substantial evidence is defined as "evidence consisting of adequate and well-controlled clinical trials on the basis of which it could be concluded that the drug will have the effect it purports or is represented to have under the conditions of use for prescribed, or proposed labeling thereof " (21 CFR 314.126). The total risk-benefit assessment is the basis for approval. Adequate and well-designed trials must show effectiveness on a clinically meaningful endpoint. Clinically meaningful endpoints directly measure how a patient feels, functions, or survives. However, to address an unmet medical need for treating a serious condition, there is a provision to develop drugs under Subpart H (21 CFR 314) and for biologics under Subpart E (21 CFR 601) through the accelerated approval pathway in the United States. Subpart H and E respectively allow drugs and biologics to be approved based on surrogate endpoints that are "reasonably likely to predict clinical benefit" or on a "clinical endpoint" that can be measured earlier than "irreversible morbidity or mortality" (IMM) that is reasonably likely to predict an effect on IMM.
Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. For a drug approved under the accelerated approval pathway, a postmarketing confirmatory trial to verify and describe the clinical benefit of the drug on the disease generally must be underway at the time of the marketing application and be completed for the drug to obtain full approval for the indication.
‡ Failure to conduct a confirmatory trial can lead to withdrawal of the drug approval.
A biomarker
§ is referred to as "candidate" surrogate, when it is still under evaluation for its ability to predict clinical benefit. A validated surrogate, on the other hand, refers to an endpoint supported by a clear mechanistic rationale and clinical data providing strong evidence that an effect on the surrogate endpoint predicts clinical benefit. Therefore, it can be used to support traditional approval. Biomarkers are referred to as "reasonably likely to predict clinical benefit" surrogates when they are accepted for use under accelerated or conditional approval to support marketing approval, but still require postmarketing studies to verify and define the clinical benefit. Particular biomarker suitability for use as a reasonably likely surrogate is decided case by case, taking into account many factors such as the mechanism of the drug and the totality of the clinical data.
The European regulatory framework has both accelerated and conditional approval components. ¶
The Conditional Approval pathway in the EU has similar criteria as the Accelerated Approval pathway in the United States, with similar requirements for unmet medical need. There are some differences in timelines and requirements for applications between the two Agencies.
Clinical Endpoints
CliNiCal BeNeFit eNDpoiNts
A clinical endpoint is a characteristic or variable that directly measures a therapeutic effect of a drugan effect on how a patient feels (e.g., pruritus reduction), functions (e.g., improved performance status), or survives (TFS). A clinical benefit is a positive therapeutic effect that is clinically meaningful in the context of a given disease. The clinical benefit must be weighed against a treatment's risks to determine whether there is an overall benefit for patients (i.e., a positive benefit-risk profile).
In PSC, clinical benefit could include improvementinoverall survival, liver TFS, and reduction in decompensation events. Reduction in the incidence of "progression to cirrhosis" on histopathology relative to placebo has been accepted by United States and European Union regulatory agencies as a clinical benefit endpoint in other liver diseases such as nonalcoholic steatohepatitis; however, the histological assessment of PSC is less well defined, and there is some concern on reliability of histological findings.
syMptoM assessMeNt
Patient surveys identify symptoms such as itch and fatigue as important causes for reduced QoL. Tools such as the Fatigue Impact Scale and 5D-itch scale for pruritus may be useful; however, these tools require further development before utilizing them in the clinical trials designed to support marketing approval. (38) Some concepts/domains of PBC-40 could be adapted and are likely to be useful in PSC, but need further validation. If these tools are used as a primary endpoint to support a marketing application, further discussion with regulatory agencies should take place before a trial is initiated.
Global assessment of QoL, which allows a higher-level assessment of the impact of disease and its symptoms, can be assessed with 36-Item Short Form Health Survey and EuroQol 5D. These tools have been validated across many diseases and populations and have the advantage of comparison with the general population. These tools could be used as secondary/ exploratory endpoints. Global assessments generally are not adequate as primary endpoints, but can be supportive. Comorbidity is a major confounding factor in QoL assessment. IBD, which accompanies PSC in up to 70% of patients, is a major comorbidity and can be assessed by measuring the Inflammatory Bowel Disease Questionnaire. See the section on Concurrent IBD.
The Amsterdam Cholestatic Complaints Score, which is a semiquantitative score covering four domains (pruritus, right-upper-quadrant pain, fatigue, and fever) has been used in several studies, but requires external validation.
CHolaNgiogRapHiC assessMeNt
The Amsterdam cholangiographic score, using a more elaborate score of disease severity of both the intra-and extrahepatic biliary tree, is thus far the only validated long-term prognostic imaging model for PSC, but has the disadvantage that it requires ERC. (8, 39) This scoring system was constructed from one cohort in The Netherlands (8) a second cohort in Norway (39) and seems a promising tool to evaluate bile duct disease. MRC is an excellent tool for diagnosis of PSC, but so far lacks evidence for accurately identifying and staging DS, or quantifying changes secondary to therapy. Staging systems for MRC are still under development. (40) (41) (42) There are no randomized trials comparing longterm outcome in PSC patients with DS with and without endoscopic treatment. Nonetheless, the occurrence of DS might be considered as a sign of worse prognosis and may have a role in assessing efficacy and safety. Given the low event rates of DS, it would be difficult to use alone as a primary endpoint. DSs should be considered a confounder of other measures, given that its occurrence and treatment may lead to changes in ALP, bilirubin, elastography readings, and symptoms. (24, 43) If symptomatic DSs are to be considered as a clinical outcome measure, it is imperative to know the baseline status of asymptomatic DS. Such asymptomatic DS could progress to symptomatic DS during the trial secondary to either worsening of the stricture or from wedging of inspissated biliary sludge. Patients with a recent history of recurrent bacterial cholangitis may require a repeat endoscopic treatment, as well as may need to be studied as separate subpopulation in clinical trials so as not to confound the results.
Potential Biomarkers
Currently, there are no validated surrogate endpoints to measure a therapeutic effect on disease progression in PSC. Hence, there is an urgent need to identify appropriate biomarkers that are reasonably likely to predict clinical benefit. PSC is a heterogeneous disease, and reliable biomarkers that can aid in stratifying and enriching patients is an equally critical unmet need.
As defined by the FDA Center for Drug Evaluation and Research (CDER), a biomarker is a "characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or biologic responses to a therapeutic intervention." Potentially reasonably likely to predict surrogate biomarkers include ALP and histological scoring systems, liver stiffness (as measured by elastography), and serum fibrosis markers as well as radiographical assessment of bile duct disease. There are several critical challenges in the evaluation of biomarkers as "reasonably likely" surrogates in PSC: (1) basic understanding of disease pathogenesis is limited; (2) PSC disease drivers have not been identified; (3) there are no biomarkers that are specifically linked to the cause of the disease; (4) phenotypic variability results in multiple different clinical outcomes such as CCA, bacterial cholangitis, DS, IBD, CRC, etc.; (5) liver fibrosis (LF) is not a sole determinant of outcomes, therefore a biomarker that measures fibrosis is not likely to capture the effects on the bile duct disease, on IBD, and their complications, which may impact clinically meaningful outcomes; (6) limited numbers of patients are available for big data approaches, as well as for gene and protein discovery; and (7) there are no validated genetic markers for severity of disease course, although, recently, genotype-phenotype analysis in a large IPSCSG cohort identified R-spondin3 (RSPO3) to be associated with TFS in PSC. (44) BioCHeMiCal MaRKeRs alp Patterns of ALP elevations are different than observed in PBC, in that there are patients who present with elevated ALP levels, which then normalize and these patients may have better outcome than those with persistently elevated ALP levels. This "spontaneous normalization" is rare in PBC.
ALP has been used as an endpoint in every clinical trial on PSC with published data in the past 20 years, either as a (part of ) the primary endpoint (n = 10) or as a secondary endpoint (n = 16); see Table 2 in Ponsioen et al. (45) Evidence for ALP as a potential surrogate endpoint for clinical trials comes from several features:
1. It is the biochemical hallmark of cholestasis, although its function is still not well understood. In PBC, there is a rise in hepatocellular bile acids secondary to reduced canalicular secretion and rise in serum ALP secondary to its release into the bloodstream rather than secretion of ALP into bile. (46) Thus, ALP is a biomarker that reflects bile acid retention in PBC patients and may reflect a similar process in PSC patients. 2. Observational studies for treatment of dominant strictures in PSC have demonstrated that ALP increases with increasing symptoms caused by DS and decreases when strictures are treated.
3. Four retrospective cohort studies, including two long-term post-hoc analyses of the negative UDCA trials, have shown that normalization of ALP level or improvement to <1.3-1.5 × upper limit of normal (ULN) is associated with better clinical outcome; see previous works. (14) (15) (16) (17) A Scandinavian UDCA trial, of 198 patients treated with UDCA or placebo for 5 years and then assessed for outcomes 10 years later in a post-hoc analysis, demonstrated that patients who achieved normalization or reduction of 40% or to 1.5 × ULN of ALP within 12 months had an improved TFS and CCAfree survival irrespective of treatment allocation. (15) This supports the conclusion that whereas UDCA may not be significantly effective in PSC, reduction in ALP levels may predict clinical benefit.
In the randomized, controlled, long-term, highdose UDCA trial of 150 patients by Lindor et al., the group treated with high-dose UDCA experienced more complications. ALP levels were reduced in the UDCA group as a whole, but the reductions in ALP were not related to the complications in individual patients. (36) However, when ALP values from individual patients were analyzed in this trial, those patients receiving high-dose UDCA who achieved ALP levels ≤1.0 × ULN at least once during follow-up had a lower risk of death and LT than those who did not. The same was observed in the placebo group. (14) The Epi PSC PBC project is a large, observational, longitudinal, retrospective cohort study of PSC and PBC in The Netherlands. All PSC patients in a defined geographical region, treated from year 2000 onward, were included. Of the 692 PSC patients included, serum ALP values at baseline and 1 year were available for 366 and 345 patients respectively. Endpoints were PSC-related death or LT. Using a systematic approach to distinguish patients with a more favorable versus poor outcome yielded a positive association between level of ALP both at diagnosis and at 1 year, and the hazard of reaching an endpoint was around 2.5 × ULN. (18) A larger decrease in ALP in the first year after diagnosis decreased the event rate. A range of thresholds (0.5-3.0 × ULN) with approximately similar C-statistics was found. The time-specific C-statistics of ALP measurements at T1 were generally higher than those of the measurements at T0, as well as compared to those of the percentage change over time. In this cohort, the optimal threshold was 1.3 × ULN at 1 year (C-statistic 0.65; 95% confidence interval [CI], 0.55-0.68). However, the population enrolled in this trial contains a broad mix of PSC patients, and a subset of the data that matched the enrollment criteria of a proposed clinical trial could potentially be used to support that absolute level of ALP at 15 months is reasonably likely to predict clinical benefit. This threshold of 1.3 comes close to earlier observations and may prove a useful for stratification in clinical trials. Interestingly, a recent article evaluating the applicability of liver stiffness measured by magnetic resonance elastography (MRE) in PSC found that ALP <1.5 × ULN excluded the presence of elevated liver stiffness. (47) Data support ALP normalization or reduction by 40%, or achieving a level less than 1.3-1.5 × ULN may be useful as a surrogate endpoint with the caveats of assessing patients at steady state and not during acute changes secondary to strictures, etc. The fact that some patients normalize ALP spontaneously should be accounted for by randomization. Clinically meaningful differences in the percentage of patients achieving a cut-off ALP value between treatment and placebo arms should be demonstrated. ALP is normal in a subset of PSC patients without cirrhosis, its utility in advanced PSC patients with cirrhosis is not entirely clear, and its role in patients who develop ALP normalization as cirrhosis progresses are other limitations. More data from large, cohort studies would be helpful to allow analysis of large numbers of patients and subgroup analysis of ALP. At this time, use of ALP as a surrogate endpoint should be supported by other biomarkers or clinical evidence of benefit.
Bilirubin
Bilirubin is considered to be less suitable as a surrogate endpoint for patients with precirrhosis PSC, because it tends to rise only in late-stage disease or temporarily in the case of suppurative cholangitis/ extrahepatic obstruction. A German study found that a persistently elevated bilirubin level for more than 3 months was significantly associated with poorer survival in both uni-and multivariate analysis, as would be expected. (7) Median TFS of these patients was only 30 months, indicating that these likely were relatively late-stage patients. However, bilirubin may be a useful biomarker when targeting stricture resolution, or in patients with late-stage disease and cirrhosis, but may not be adequate as a stand-alone evaluation. More natural history data would be useful for evaluating the potential of bilirubin for predicting clinical outcomes.
enhanced liver Fibrosis score
Recently, the Enhanced Liver Fibrosis (ELF) score, a panel of three serum markers of fibrosis-hyaluronic acid, procollagen III aminoterminal peptide, and tissue inhibitor of metalloproteinase 1-was tested for its discriminative performance with regard to death or LT in a Norwegian study comprising 305 large-duct PSC patients divided in a training set of 167 patients collected between 1992 and 2006 and a validation cohort of 138 patients collected between 2008 and 2012. (48) The ELF test distinguished between mild and severe disease defined by clinical outcome (transplantation or death) with an area under the curve (AUC) of 0.81 (95% CI, 0.73-0.87) and optimal cutoff of 10.6 (sensitivity, 70.2%; specificity, 79.1%). A validation study in external cohorts from seven countries confirmed the previous data. (49) As with other serum biomarkers, ELF can be elevated secondary to acute inflammation or obstruction, and these need to be accounted for assessing responses.
gamma-glutamyl transpeptidase and pediatric psC
The situation in childhood is different from that of adults. Use of ALP as a biomarker of biliary disease in pediatric PSC is not reliable, and gGT is considered a more specific marker for bile duct injury in the pediatric setting for several reasons: (1) In four retrospective series, only 53%-81% of patients had an elevated ALP at diagnosis compared to 94%-100% of children with elevated gGT. (50) (51) (52) (53) ( 2) The range of normal ALP levels increases substantially during rapid bone growth, making any single elevated ALP difficult to interpret in children, although fractionation could overcome this difficulty. (3) Serum gGT levels have shown prognostic value in pediatric patients in several other cholestatic conditions, such as total parenteral nutrition-related liver disease, idiopathic neonatal hepatitis, and sepsis-related cholestasis. gGT is also found in the kidney and pancreas; however, gGT is commonly used as a diagnostic marker of hepatobiliary injury and cholestatic and biliary diseases. Sheehan et al. published data demonstrating that gGT has a high sensitivity with a low false-negative rate in the diagnosis of a cholestatic disease.
(54) (4) gGT appears to be a more sensitive marker of PSC in children as compared to ALP, according to two retrospective chart reviews of PSC patients treated with UDCA. (51, 55) 
serum autoantibodies and igg
Autoimmune sclerosing cholangitis or PSC/AIH overlap syndrome is quite common in children, with prevalences ranging from 25% to 75%. (50) (51) (52) It is recommended that all children with a presumptive diagnosis of sclerosing cholangitis be screened for AIH with serum autoantibodies (antinuclear antibodies, anti-smooth muscle antibody, liver-kidney microsomal antibody, and total IgG level) and, if positive, undergo a liver biopsy. Interestingly, although treatment of the AIH component will result in normalization of all liver tests, autoantibody titers, and IgG level in >70% of cases, structural abnormalities of the bile ducts remain or progress over time, suggesting that autoantibodies and total IgG are diagnostic biomarkers of AIH; however, their use as a prognostic indicator for PSC appears to be limited. (56) 
MelD score
The MELD score has been used around the world to list and prioritize patients with ESLD for LT since 2002. (14) The model also holds for PSC in estimating 3-month mortality. (15) A problematic issue in the setting of PSC is that MELD is driven by bilirubin level. MELD score may be temporarily increased because of bile plugging or a DS and/or bacterial cholangitis. This condition may require endoscopic treatment and/ or antibiotics upon which bilirubin commonly returns back to previous levels. Hence, in determining the MELD score, measures must be taken to ensure that a patient is in steady state. MELD may not be as sensitive in this population given that patients with PSC tend to develop portal hypertension before development of cirrhosis. Despite all the limitations noted above, a change in MELD score could be potentially considered as a surrogate endpoint, especially in more-advanced cases.
elastogRapHy
Several imaging tools with a potential to be used either for stratification or surrogate endpoints have emerged. Liver stiffness, as measured by elastography, is a marker for hepatic fibrosis. Liver stiffness can be quantified by vibration-controlled transient elastography (VCTE), MRE, or point shear wave elastography (pSWE). Corpechot et al. published their findings in a single-center trial in 167 PSC patients; VCTE correlated well with Metavir stage, performing best at extreme stages, with an area under the receiver operating curve (AUROC) to distinguish severe fibrosis (Metavir F3-F4) from lower stages >0.90. (57) In addition, baseline values and, even more interesting, rate of change over time were correlated with clinical outcome. The study excluded patients with DS and acute cholangitis. These results need prospective validation, which is currently being performed by the international 5-year prospective FICUS cohort study within the IPSCSG. A recent study from Germany reported findings similar to those of Corpechot et al. and demonstrated good performance for diagnosis and exclusion of higher fibrosis stages (≥F3) with an AUROC of 0.95. (58) Baseline data on VCTE from a phase 2 simtuzumab trial were recently presented (ClinicalTrials. gov NCT01672853). In line with and using the same cutoff as Corpechot et al., baseline transient elastography (TE) had a negative predictive value of 100% for distinguishing Ishak F0-F4 from F5-F6, thereby effectively excluding cirrhosis. (59) VCTE meets several desired qualifications for a biomarker, in that it is a practical, cheap, rapid, noninvasive bedside measure and is reproducible. VCTE has been approved by the FDA for measuring kilopascals (kPa) accurately on the basis of tests carried out in phantoms with known attenuations. This method is not yet approved to diagnose fibrosis or fibrosis stage. A limitation, as for many noninvasive techniques, is operator inexperience. In large-duct biliary obstruction or acute inflammation of the liver, VCTE can rise significantly, but is only reflective of increased intraductal pressure and/or acute inflammation and is not a measure of fibrosis during these acute episodes. (60) Treatment of DS leads to a substantial decrease in VCTE level. The variability of repeat measures is not yet established in the PSC population. Although a promising biomarker, these limitations would need to be accounted for in desi g n of the endpoint using any elastography method. (60, 61) Ultrasound with pSWE uses acoustic radiation force impulse technology, with the advantage of being incorporated into high-end ultrasound equipment, combining B-mode ultrasound guidance of elastography measurements, enabling full evaluation of the liver, spleen, and portal vein. In a pilot study, pSWE was shown to discriminate between PSC patients and healthy controls with an AUROC of 0.78. (62) An alternative way of gauging liver stiffness is by MRE. In the only published study, liver stiffness correlated with histological fibrosis stage in 20 PSC patients and was predictive of hepatic decompensation in a series of 266 PSC patients. (47) The AUC for detection of cirrhosis was 0.99 with a cut-off (kPa) of 4.93. In addition, increased liver stiffness assessed by MRE was associated with the development of decompensated liver disease (hazard ratio [HR], 1.55; 95% CI, 1.41-1.70). Of note, patients with an untreated DS (n = 21) had a higher median liver stiffness compared with patients without, which lowered substantially in 3 of 4 endoscopically treated patients. These results require further validation.
In other liver diseases, MRE has appeared to be more accurate than VCTE in identifying liver cirrhosis and LF. The main limitations of MRE are high costs and limited availability. However, MRE can be combined with MRC in a single procedure without adding significant cost and time, and both liver stiffness and bile duct anatomy can be evaluated simultaneously.
iMagiNg
MRC has largely replaced endoscopic ERC for diagnosis of large-duct PSC, because it is noninvasive. Despite its high accuracy for diagnosing PSC, its resolution was believed too low for measuring changes over time. However, a recent study by Ruiz et al., evaluating annual three-dimensional MRC, showed that 60% of patients developed progressive changes over 4 years. (42) A recent study used dynamic gadoxetate-enhanced MRI for assessment of total and segmental liver function and volume in PSC. (63) Pharmacokinetic studies show thatapproximately 50% of the administered dose of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid is extracted by the liver and eliminated through the hepatobiliary pathway. (64) Liver function was significantly more heterogeneously distributed among PSC patients in this study, and hepatic extraction fraction showed a statistically significant negative correlation with biliary obstruction.
other imaging Modalities
Spleen size has recently been reported as an easy-toobtain and reproducible measure of portal hypertension. For a cutoff of 120 mm, spleen size measured by ultrasound or on MRI was correlated with patient outcome; PSC patients with a spleen size over 120 mm had a median TFS of only 5.2 years. (65) These researchers recently expanded their series to a combined German/ French cohort of 210 PSC patients and found the same adequate Harell's c-statistics for both TE as for spleen length with regard to its predictive power (liver-related death, LT, and hepatic decompensation). (58) However, these data are preliminary and, at this time, are not adequate to support spleen size as a surrogate for clinical trials.
Histology
Histology has been the gold standard for grading liver inflammation and staging LF for many liver diseases. Liver biopsy is no longer regarded necessary for diagnosis of typical cases of PSC, but remains important for diagnosing variants such as small-duct PSC and overlap syndromes with AIH. (2) In the setting of PSC, the predominant grading feature is inflammation, which is mainly present in portal tracts, and may be associated with varying degrees of interface hepatitis. However, most prominent pathology usually takes place in the larger bile ducts, which are not accessible by standard percutaneous liver biopsy. In contrast, the most widely used staging feature is fibrosis, which can be assessed in peripheral liver tissue. Other relevant features include bile duct loss and accumulation of copper-associated protein in periportal hepatocytes indicative of cholestasis. (66) Histological features have been used in 12 published clinical trials of PSC. None of these studies allowed a comparison of change in stage or grade with clinical outcome.
Data to support that change in histological grading and staging may predict clinical benefit and have the potential to be utilized as surrogate endpoints include four observational peer-reviewed publications with long-term follow-up from the 1990s comprising 826 cases that looked into the association of histological stage with clinical outcome. (67) (68) (69) (70) All four studies showed that Ludwig stage was independently associated with death and/or LT.
Unfortunately, no one single system for histological grading and staging of PSC has been widely accepted. Ishak and Ludwig systems have been used in the past. Recently, the Ishak, Ludwig, and a staging system for PBC described by Nakanuma et al., (71) which incorporates features indicative of disease progression in chronic biliary diseases such as fibrosis, ductopenia, and orcein-positive granules, were assessed in 64 PSC patients as to its ability to predict clinical outcome. (72) Strong associations were shown between disease stage measured by Ishak, Nakanuma, and Ludwig staging systems with both TFS (HR 2.56, 95% CI 1.11-5.89; HR 6.53, 95% CI 2.01-21.22; and HR 1.94, 95% CI 1.00-3.79, respectively) and time to LT (HR 4.18, 95% CI 1.51-11.56; HR 7.05, 95% CI 1.77-28.11; and HR 3.13, 95% CI, 1.42-6.87, respectively). Nakanuma staging appeared to hold the best prognostic value. An external validation and interobserver variability assessment study using samples from seven European centers confirmed these findings and also showed that all three staging systems have adequate kappas (Nakanuma stage κ = 0.56, Nakanuma component fibrosis κ = 0.67, Ishak stage κ = 0.64, and Ludwig stage κ = 0.62). (73) A survey among the eight European expert liver pathologists involved in both studies revealed that all favored the Nakanuma scoring as the preferred histological staging system for PSC.
Liver biopsy has a number of limitations. Biopsy is an invasive procedure not devoid of adverse events that is frequently painful for patients. However, mortality is low (less than 1 in 10,000), and serious adverse event rate is less than 0.5% if performed under ultrasound guidance. With regard to the patient's reluctance to participate in trials requiring liver biopsy, it is noteworthy that the phase 2 simtuzumab trial (NCT01672853) was able to complete recruitment of 234 study subjects in 1.5 years despite requiring liver biopsies at baseline and at weeks 48 and 96.
Olsson et al. specifically looked into discord of staging within multiple biopsies. (74) The researchers recommended taking two biopsies for clinical trials. It was also suggested to perform follow-up biopsies at the same site given the frequent regional differences in disease activity in PSC with one atrophic and contralateral hypertrophic lobe. Ultrasound can accurately localize the same segment of the liver with no additional cost or radiation. This needs to be taken into consideration while planning histological endpoints.
In a longitudinal series of 107 patients with repeated biopsies from the Mayo clinic, Angulo et al. estimated, by using a Markov model, that 66% and 93% of patients with Ludwig stage II would progress to stage III or IV after 2 and 5 years respectively. (75) These data support the notion that changes in histology can be observed in a reasonable time.
Morphometric assessment, such as collagen proportionate area, has demonstrated a positive correlation between the amount of fibrosis in cirrhotic liver and the relative hepatic vein pressure gradient and liver tissue stiffness in steatohepatitis and chronic viral hepatitis. (76) Baseline hepatic collagen content was also shown to correlate with Ishak fibrosis stage and has a potential to evaluate progression of fibrosis; however, the data are still preliminary. (77) With regard to grade, two recent studies showed a poor correlation between Ishak and Nakanuma grade and outcome. (72, 73) Therefore, whereas change in fibrosis stage is supported by data as a potential surrogate endpoint for PSC, there are currently lack of data to support that a change, or degree of change in the histological grade, is predictive of clinical outcomes. Improvements in histological grade would need to be supported by other assessments to assure that there is not worsening of other components of this complex disease.
ipsCsg ReCoMMeNDatioNs
The IPSCSG published the results of a consensus process among leading scientists with the purpose of identifying the most appropriate candidate surrogate endpoints for clinical trials. (45) A combination of changes in ALP and histology as co-primary endpoint was considered advisable by the IPSCSG in the absence of an established single surrogate endpoint. The IPSCSG proposed that this would offer reassurance that, if both endpoints change in the predefined direction, this will support a treatment effect and vice versa. (78) A peripheral liver biopsy may provide information on the stage of fibrosis, but is not informative about the degree of extrahepatic obstruction, whereas ALP levels may provide information on inflammation (indirect measure) and stricturing in the bile duct.
An anti-inflammatory drug mechanism would be expected to decrease ALP, but not improve fibrosis. On the other hand, a drug with an antifibrotic mechanism would be expected to improve or slow progression in fibrosis, but potentially may not affect inflammatory changes on histology.
Designing Future Trials
Next to clinical phenotype characteristics, such as small-duct versus large-duct PSC and concurrent Crohn's disease versus ulcerative colitis, stratification of patients for enrollment could be performed using biomarkers-ALP, histological stage, FibroScan, and MELD, as well as clinical biomarkers.. Three main confounders that can affect the relationship between specific exposures and outcomes in PSC that should be considered while designing clinical trials are: (1) cholangitis, which will impact biochemical markers (e.g., ALP, alanine transferase, and total bilirubin) and may be a clinical endpoint; (2) CCA, which will impact clinical outcome as competing risk in individual patients; and (3) colitis activity may influence QoL measurements and may be worsened by the investigational treatment.
For proof-of-concept trials, a shorter-duration trial may be sufficient depending on drug mechanism. It is reasonable to assess several biomarkers thought to be on the mechanistic pathway to evaluate for initial evidence for safety and efficacy. For phase 3 trials aimed at improving long-term outcome, the optimal duration will depend on the presumed mode of action of the drug and the endpoints. Phase 3 trials with endpoints measuring symptoms as a primary clinical outcome could potentially have shorter trial durations.
System biology approaches using the omics tools may be of pivotal importance for incorporating in clinical trial designs as exploratory endpoints. This strategy will help in scientific understanding of the pathophysiology of PSC.
MeasURiNg CliNiCal BeNeFit
A composite endpoint, as opposed to a co-primary endpoint, is a combination of various clinical events where any individual event would count as satisfying the composite endpoint. When composed of validated clinical events, a composite primary endpoint can augment the chance of a positive outcome in a clinical trial with a drug aimed at slowing down disease progression. As such, combining clinical endpoints (transplant, all-cause mortality, and decompensation events) with other markers of morbidity (progression to cirrhosis, progression of MELD score from ≤12 to ≥15) has the potential to offer a feasible composite endpoint for regular approval in phase 3 or 4 trials in a population of patients with precirrhosis.
Other targets of drugs for PSC could be pruritus and fatigue. These conditions could be used as clinical endpoints for full approval; however, if the mechanism of the drug does not affect underlying disease progression, treating symptoms alone may have only transient benefit and this would need to be considered in the overall risk/benefit evaluation. In addition, in small subpopulations (e.g., pediatric PSC), endpoints that measure the major symptoms that are affecting an individual patient may need to be designed, thus structuring a trial with several different endpoints that can be individualized to the patient and drug mechanism.
Conclusions
Regulatory agencies offer reasonable strategies that can be used to design clinical trials in patients with PSC and even in subgroups with rare phenotypes. There have been no phase 3 trials initiated to date; however, several drugs are now in the pipeline. Several potential candidate surrogate biomarkers as discussed above may be appropriate to use as "reasonably likely to predict" surrogate endpoints for phase 3 trials depending on the drug mechanism and target. Because of the underlying complexity of PSC, surrogate endpoints that measure more than one aspect of the disease may be appropriate (i.e., bile duct pathology and LF). An example of a potential combined "reasonably likely to predict" surrogate endpoint would be improvement in serum ALP levels and assessment of progression of fibrosis/cirrhosis using either noninvasive methods (e.g., TE) or histology. Other combinations of biomarkers and clinical outcomes may be acceptable and can be proposed as multiple endpoints or composite endpoints for the larger phase 2b and marketing trials under an accelerated approval pathway.
Patients are interested not only in drug development that targets the underlying disease pathology and risk for both progression to cirrhosis and cancer, but also in drugs that target symptoms of fatigue and pruritus that make day-to-day living difficult. Clinical trials that target these symptoms have the potential to require shorter-duration trials than ones that aim to affect the underlying disease.
Symptom assessment may also be used as an intermediate clinical endpoint for accelerated approval with a drug that has the potential to affect both symptoms and the underlying disease progression.
Regulatory agencies are open to potentially novel clinical trial designs for rare diseases. Data to support that the surrogate endpoint(s) are on the mechanistic pathway of the disease and reasonably likely to predict clinical benefit of treatment will need to be provided by each investigator to the regulatory agencies. Further improvement in technology and continued collaborative collection of data and clinical validation will be important in gathering information to support the use of surrogate endpoints. Drugs approved under an accelerated or conditional approval pathway using a "reasonably likely to predict" surrogate endpoint are generally required to have a clinical trial underway to verify and describe the clinical benefit of the drug at the time of the marketing approval.
